Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk. Wien Klin Wochenschr. 2019 Aug 14;: Authors: Stühlinger MC, Weltermann A, Staber P, Heintel D, Nösslinger T, Steurer M Abstract Ibrutinib is the first clinically approved inhibitor of Bruton's tyrosine kinase, an enzyme that is essential for survival and proliferation of B‑cells by activating the B‑cell receptor signalling pathway. Ibrutinib has been shown to be highly effective in B‑cell malignancies in clinical trials and is recommended in current international guidelines as a first and/or second line treatment of chronic lymphocytic leukemia. The drug has a favorable tolerability and safety profile but the occurrence of specific side effects (e.g. atrial fibrillation, bleeding and hypertension) may complicate or be of concern for doctors and patients considering the use of this treatment. In many cases, however, it is not necessary to withhold this effective therapy. In contrast, ibrutinib treatment can be initiated or continued, if certain recommendations are followed. The possibilities of prevention, diagnosis and management of specific clinical situations are discussed in detail and recommendations are derived, which should facilitate ibrutinib use. PMID: 31414181 [PubMed - as supplied by publisher]
Publication date: Available online 15 September 2019Source: Advances in Biological RegulationAuthor(s): Samuel Gusscott, Francesco Tamiro, Vincenzo Giambra, Andrew P. WengAbstractT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer, characterized by an uncontrolled expansion and accumulation of T-cell progenitors. During leukemic progression, immature T cells grow abnormally and occupy the bone marrow compartment, thereby interfering with the production of normal blood cells. Pediatric T-ALL is curable with intensive chemotherapy, but there are significant, long-term side effects and ∼20% of patients suf...
We reported the surgical repair of bilateral CDH in a male infant aged 6 weeks. The patient had herniation of the liver on the right side with HPF in association with anomalous drainage of the right pulmonary vein into the hepatic vein and ventricular septal defect. We approached both sides thoracoscopically; however, the right side required a subcostal incision. We separated the liver from the right lower lung lobe laterally using electrocautery, and the defect was closed with a mesh. The medial portion was left intact to avoid injury of the anomalous pulmonary venous drainage. After 2 weeks, the patients had a surgi...
CONCLUSION: The patients' sleep quality worsened and their daytime sleepiness increased as the risk of malnutrition increased. PMID: 31522220 [PubMed - in process]
' There's once again excitement about renal artery denervation and … it's justified,'says one cardiologist, while another hopes for FDA approval next year, and a third is'still not 100% convinced. 'theheart.org on Medscape
Conditions: Atrial Fibrillation; Surgery--Complications Intervention: Diagnostic Test: Cardiac examination programme 3 months after abdominal surgery Sponsor: Frederiksberg University Hospital Not yet recruiting
Conditions: Atrial Fibrillation; Surgery--Complications Intervention: Diagnostic Test: Holter monitoring Sponsor: Frederiksberg University Hospital Not yet recruiting
Conditions: Pulmonary Arterial Hypertension; Right-Sided Heart Failure Intervention: Other: PET/MRI Sponsors: University of Wisconsin, Madison; United Therapeutics Recruiting
Condition: Leukemia, Myeloid, Acute Interventions: Drug: Pevonedistat; Drug: Azacitidine Sponsors: PETHEMA Foundation; Millennium Pharmaceuticals, Inc.; Dynamic Science S.L. Recruiting
Conditions: Advanced Malignant Solid Neoplasm; Caregiver; Metastatic Malignant Solid Neoplasm; Recurrent Leukemia; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Plasma Cell Myeloma Intervention: Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
Conclusion: Acalabrutinib monotherapy produced high response rates and demonstrated an acceptable safety profile in patients with TN CLL.DisclosuresFurman: Gilead: Consultancy; Loxo Oncology: Consultancy; Acerta: Consultancy, Research Funding; Genentech: Consultancy; Pharmacyclics LLC, an AbbVie Company: Consultancy; Sunesis: Consultancy; TG Therapeutics: Consultancy; Verastem: Consultancy; Incyte: Consultancy, Other: DSMB; Janssen: Consultancy; AbbVie: Consultancy. Martin: Gilead: Consultancy; Janssen: Consultancy; Bayer: Consultancy; Seattle Genetics: Consultancy; AstraZeneca: Consultancy; Kite: Consultancy. O'Brien: Jan...